Get the Stockscreener App
11.82
4.14%
-0.51
Telix Pharmaceuticals Ltd Adr stock is traded at $11.82, with a volume of 120.17K.
It is down -4.14% in the last 24 hours and up +7.26% over the past month.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
See More
Previous Close:
$12.33
Open:
$11.96
24h Volume:
120.17K
Relative Volume:
0.78
Market Cap:
$4.00B
Revenue:
$804.63M
Net Income/Loss:
$-7.13M
P/E Ratio:
-560.19
EPS:
-0.0211
Net Cash Flow:
$-73.42M
1W Performance:
+2.60%
1M Performance:
+7.26%
6M Performance:
+80.73%
1Y Performance:
+7.55%
1-Day Range:
$11.75
$11.99
1-Week Range:
$11.67
$12.33
52-Week Range:
$6.28
$12.60
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Name
Telix Pharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare TLX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
11.82 | 4.06B | 804.63M | -7.13M | -73.42M | -0.0211 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Citigroup | Buy |
| Aug-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-03-25 | Initiated | H.C. Wainwright | Buy |
| Jun-05-25 | Initiated | Wedbush | Outperform |
| Nov-15-24 | Initiated | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Latest News
Telix R&D Day to Feature Pipeline Updates and Outside Experts - Stock Titan
Telix H1 2026 Results: Investor Webcast Notification - Sahm
Study Tests Imaging to Select Patients for Telix Prostate Therapy - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals (ASX:TLX) Targets More Than US$1 Billion in Revenue and Other Income After Quarterly Revenue Jumps 21% - Kalkine
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewswire Inc.
Telix Starts Phase 3 Targeted Radiation Study for Kidney Cancer - Stock Titan
Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA trial progress - Investing.com
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention - Kalkine
Telix Pharmaceuticals (ASX:TLX): Radiopharmaceutical Innovator Pauses in a Rising Sector - Kalkine
FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design - Stock Titan
Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update - Kalkine
Telix gets FDA alignment on prostate cancer trial expansion to US - Investing.com
Telix Pharmaceuticals Limited Sponsored ADR Actuals & Estimates (NASDAQ:TLX) - TradingView
Telix webinar spotlights glioblastoma care and theranostics next week - Stock Titan
ASX Healthcare Sector Rally: CSL, ResMed and Telix Advance on Broad Market Strength - Kalkine
AI-enhanced cancer scans: Telix and United Imaging team up on theranostics - Stock Titan
Prostate cancer trial: Telix therapy shows acceptable safety in combo treatment - Stock Titan
Telix CEO lines up back-to-back investor talks in Chicago and New York - Stock Titan
TLXTelix Pharmaceuticals Ltd ADR Stock Price and Quote - Finviz
TLX SEC FilingsTelix Pharmaceuticals Ltd ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Telix Pharmaceuticals Ltd stock (AU000000TLX2): FDA filing advances - Ad-hoc-news.de
Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K - Stock Titan
Telix Pharmaceuticals (TLX) director Form 3 shows no share trades - Stock Titan
Telix Pharmaceuticals (TLX) director Jellison files initial Form 3 ownership - Stock Titan
Maria Rivas joins Telix Pharmaceuticals (TLX) board and files initial Form 3 - Stock Titan
Prostate cancer imaging tie-up aims to cut incontinence, impotence risks - Stock Titan
Can Telix Pharmaceuticals (ASX:TLX) Regain Momentum Ahead of Key FDA Decision? - Kalkine
Telix (TLX) CEO boosts indirect stake with 67,935-share open-market buy - Stock Titan
Kidney cancer scan showed 98% positive predictive value in analysis - Stock Titan
Europe begins 210-day review of Telix brain cancer imaging candidate - Stock Titan
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - Sahm
US$600M Telix Pharmaceuticals (TLX) convertible bond settlement noted - Stock Titan
TLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Telix Pharmaceuticals (TLX) files 6-K on AGM and proxy materials - Stock Titan
Telix’s Phase 3 prostate cancer study gets a late-breaking ASCO slot - Stock Titan
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Sahm
First radiopharmaceutical enters Phase 3 for recurrent brain cancer - Stock Titan
Regeneron taps Telix in $40M push for next-generation cancer drugs - Stock Titan
Telix Pharmaceuticals stock gains on FDA acceptance of NDA - Investing.com
Telix Pharmaceuticals stock gains on FDA acceptance of NDA By Investing.com - Investing.com South Africa
Telix Pharmaceuticals Shares Jump 7% on FDA Nod for Brain Cancer Imaging Agent Amid Strong Revenue Momentum - International Business Times Australia
Revenue growth on track for undervalued ASX healthcare stock - Morningstar Australia
Brain cancer imaging agent moves toward FDA decision by Sept. 11 - Stock Titan
Former Pfizer and Stryker leaders join Telix board expansion - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on revenue growth - Investing.com
Telix Pharmaceuticals Ltd Adr Stock (TLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):